AI diagnostics, brain-computer interfaces, gene editing, and the future of medicine.
103 articles
Tilrekimig, an investigational trispecific antibody, produced EASI-75 responses of 47.8% to 62.5% at week 16 in a Pfizer Phase 2 atopic dermatitis study, versus 9.1% to 19.9% on placebo.
The Watertown, Massachusetts biotech is halting the SMARCA2 inhibitor FHD-909 after Phase 1 data fell short, ending a Lilly alliance once valued at up to $1.6 billion and shedding about 40 percent of staff.
Detailed Phase 3 results show the investigational triple agonist produced average weight loss of 20.8 percent at 80 weeks alongside sharp A1C reductions in adults with type 2 diabetes and obesity.
Egetis Therapeutics won US clearance for Emcitate (tiratricol), a once daily liquid suspension for a rare X-linked disorder, with supply expected within ten weeks.
The Democratic Republic of the Congo has recorded 8,067 confirmed Ebola cases and 3,901 deaths, the worst outbreak in its history, as the EU and the United States pledged new funding.
Mirum and Incyte win U.S. approval for a once-daily ALK2 inhibitor that becomes only the third therapy cleared for an ultra rare genetic bone disorder.
The US regulator cleared tavapadon as a once-daily pill for early and advanced Parkinson's disease, marking the first selective D1/D5 partial agonist and a new oral class after roughly 30 years.
Merck and Eisai won U.S. approval for a dual oral regimen that pairs a HIF-2 alpha inhibitor with a tyrosine kinase inhibitor in previously treated kidney cancer.
A dose-response meta-analysis of 51 cohorts covering 8,819,894 adults found that each additional 100 grams of ultra-processed food per day carried higher risks for heart disease, cancer and death.
Novo Nordisk said once weekly CagriSema 1.0 mg/1.0 mg produced 12.4% average weight loss versus 9.1% for Eli Lilly tirzepatide 5 mg at week 60 in the phase 3 REIMAGINE 5 trial in type 2 diabetes.
Roche's once-weekly enicepatide met both main goals of a 447-patient Phase II study, positioning the dual GLP-1/GIP agonist for late-stage trials against Lilly and Novo Nordisk.
Beacon Therapeutics said its one-time gene therapy laru-zova met the main goal of the VISTA study in XLRP, with 31 percent of high dose patients gaining low-light vision.
A cohort study of 95,559 UK Biobank adults followed for a median of 8.9 years links more REM and deep sleep to lower risk for dozens of conditions, with the lowest risk at six to eight hours.
Eli Lilly's Inluriyo combined with Verzenio wins full FDA approval for ESR1 mutated advanced breast cancer, offering an all oral regimen that doubled median progression free survival in the EMBER-3 trial.
The U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) on September 17, 2026, giving adults with chronic kidney disease linked to type 1 diabetes their first new drug option in more than 30 years.
Ultragenyx priced its newly approved one-time gene therapy at $3.95 million after the FDA cleared the first treatment designed to change the course of the fatal childhood brain disease.
Fiji recorded 2,016 new HIV diagnoses in 2025, a 27 percent jump, while one in 60 adults is estimated to be living with the virus, prompting a national emergency and new harm-reduction plans.
The 32.5 mm ventricular device is 14 percent shorter than Abbott's prior 38.0 mm Aveir VR and expands implant options for patients with slow heart rhythms.
Telix Pharmaceuticals won U.S. approval for Pixclara, a fluorine-18 amino acid PET agent that helps doctors tell recurrent glioma apart from treatment-related changes.
How a county coroner's finding in Jefferson County pushed Pennsylvania to its third measles-associated death of the year and deepened a fight with federal health officials over the count.
Scholar Rock won U.S. approval for ISEMBYLD, an antibody that blocks myostatin and becomes the first SMA treatment aimed at preserving muscle in patients already on SMN2 therapies.